RVTY - Revvity, Inc.
Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?
RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while software ARR grew in the mid-20% range, offsetting Life Sciences weakness and China exit headwinds. Operating leverage is strong, with 13% EPS growth on 3% organic revenue growth and free cash flow conversion exceeding 100%, supporting deleveraging and strategic reinvestment.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. The Signals LabGistics offering uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. As.
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior management team will provide updates on the Company's key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations webs.
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o.
Revvity Inc. (NYSE: RVTY - Get Free Report) shares reached a new 52-week high on Thursday. The stock traded as high as $158.28 and last traded at $153.6540, with a volume of 4432400 shares trading hands. The stock had previously closed at $152.77. Analyst Ratings Changes A number of analysts have issued reports on RVTY shares.
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k.
Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Institutional and Insider Ownership 86.7% of Revvity shares are held
State Street Corp boosted its stake in Revvity Inc. (NYSE: RVTY) by 0.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,342,739 shares of the company's stock after acquiring an additional 32,426 shares during the period. State Street Corp owned 3.89%
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Analyst Recommendations This is a summary of current recommendations
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
California State Teachers Retirement System increased its holdings in Revvity Inc. (NYSE: RVTY) by 10,607.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,328,063 shares of the company's stock after buying an additional 14,194,254 shares during the quarter. California